Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 7 September 1979:
Vol. 205. no. 4410, pp. 1025 - 1027
DOI: 10.1126/science.472724
Prev | Table of Contents | Next

Articles

Science, Vol 205, Issue 4410, 1025-1027
Copyright © 1979 by American Association for the Advancement of Science

articles

3-Methoxy-4-hydroxyphenethyleneglycol production by human brain in vivo

JW Maas, SE Hattox, NM Greene, and DH Landis

A direct method has been employed to estimate the rate of production by human brain of 3-methoxy-4-hydroxyphenethyleneglycol, the major metabolite of brain norepinephrine, a brain neurotransmitter. Venous specimens were obtained from the internal jugular vein from ten awake human subjects at a puncture site above the common facial vein, the first major source of extracranial inflow. Arterial specimens were simultaneously obtained from the radial artery. Plasma samples were assayed and a highly significant difference was found in the concentration of the metabolite in plasma coming out of the brain (venous blood) as compared to plasma entering the brain (arterial blood). This venous-arterial difference was calculated to be 0.7 +/- 0.1 nanogram per milliliter of blood. Assuming an adult brain weight of 1400 grams and normal cerebral blood flow, it is estimated that the rate of production of 3-methoxy-4-hydroxyphenethyleneglycol by the awake human brain is approximately 597 nanograms per minute or 35.8 micrograms per hour. Urine specimens were also collected from six of these subjects during a period of 1 to 3.5 hours, which bracketed the time the blood samples were obtained. For these six subjects the output of 3-methyoxy-4-hydroxyphenethyleneglycol by whole brain was estimated to be 40.9 micrograms per hour, whereas the rate of its excretion into urine was 64.5 micrograms per hour.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Elevated Brain Serotonin Turnover in Patients With Depression: Effect of Genotype and Therapy.
D. A. Barton, M. D. Esler, T. Dawood, E. A. Lambert, D. Haikerwal, C. Brenchley, F. Socratous, J. Hastings, L. Guo, G. Wiesner, et al. (2008)
Arch Gen Psychiatry 65, 38-46
   Abstract »    Full Text »    PDF »
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine.
G. Eisenhofer, I. J. Kopin, and D. S. Goldstein (2004)
Pharmacol. Rev. 56, 331-349
   Abstract »    Full Text »    PDF »
Attention-Deficit Hyperactivity Disorder.
L. K. Laird and J. J. Saklad (1990)
Journal of Pharmacy Practice 3, 241-251
   Abstract »    PDF »
Plasma 3-Methoxy-4-Hydroxyphenylglycol Changes Associated With Clinical State and Schizophrenic Subtype.
G. N. Ko, D. C. Jimerson, R. J. Wyatt, and L. B. Bigelow (1988)
Arch Gen Psychiatry 45, 842-846
   Abstract »    PDF »
{alpha}2-Adrenergic Receptor Sensitivity in Depression: The Plasma MHPG, Behavioral, and Cardiovascular Responses to Yohimbine.
G. R. Heninger, D. S. Charney, and L. H. Price (1988)
Arch Gen Psychiatry 45, 718-726
   Abstract »    PDF »
Carbon Dioxide--Induced Anxiety: Behavioral, Physiologic, and Biochemical Effects of Carbon Dioxide in Patients With Panic Disorders and Healthy Subjects.
S. W. Woods, D. S. Charney, W. K. Goodman, and G. R. Heninger (1988)
Arch Gen Psychiatry 45, 43-52
   Abstract »    PDF »
Afternoon Continuous Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol and Age: Distinctive Biologic Subgroups of Endogenous Depression?.
U. Halbreich, N. Sharpless, G. M. Asnis, J. Endicott, S. Goldstein, J. Vital-Herne, J. Eisenberg, K. Zander, B.-J. Kang, R. Shindledecker, et al. (1987)
Arch Gen Psychiatry 44, 804-812
   Abstract »    PDF »
Plasma Monoaminergic Metabolites and Catecholamines in Subarachnoid Hemorrhage: Clinical Implications.
A. Minegishi, T. Ishizaki, Y. Yoshida, A. Ahagon, N. Shibata, and H. Kobayashi (1987)
Arch Neurol 44, 423-428
   Abstract »    PDF »
Catecholamine Metabolism and Disposition in Healthy and Depressed Subjects.
J. W. Maas, S. H. Koslow, J. Davis, M. Katz, A. Frazer, C. L. Bowden, N. Berman, R. Gibbons, P. Stokes, and D. H. Landis (1987)
Arch Gen Psychiatry 44, 337-344
   Abstract »    PDF »
Lithium Carbonate Treatment of Mania: Cerebrospinal Fluid and Urinary Monoamine Metabolites and Treatment Outcome.
A. C. Swann, S. H. Koslow, M. M. Katz, J. W. Maas, J. Javaid, S. K. Secunda, and E. Robins (1987)
Arch Gen Psychiatry 44, 345-354
   Abstract »    PDF »
Situational Panic Attacks: Behavioral, Physiologic, and Biochemical Characterization.
S. W. Woods, D. S. Charney, C. A. McPherson, A. H. Gradman, and G. R. Heninger (1987)
Arch Gen Psychiatry 44, 365-375
   Abstract »    PDF »
Norepinephrine and Dopamine Metabolites and Educational Variables in Boys With Attention Deficit Disorder and Hyperactivity.
W. O. Shekim, E. Sinclair, R. Glaser, E. Horwitz, J. Javaid, and D. B. Bylund (1987)
J Child Neurol 2, 50-56
   Abstract »    PDF »
Noradrenergic Function and the Mechanism of Action of Antianxiety Treatment: II. The Effect of Long-term Imipramine Treatment.
D. S. Charney and G. R. Heninger (1985)
Arch Gen Psychiatry 42, 473-481
   Abstract »    PDF »
Increased Anxiogenic Effects of Caffeine in Panic Disorders.
D. S. Charney, G. R. Heninger, and P. I. Jatlow (1985)
Arch Gen Psychiatry 42, 233-243
   Abstract »    PDF »
Excretion of Catecholamine Metabolites During Methadone Maintenance and Withdrawal.
F. A. De Leon-Jones, J. M. Davis, E. E. Inwang, and H. Dekirmenjian (1983)
Arch Gen Psychiatry 40, 841-847
   Abstract »    PDF »
Impaired Presynaptic Regulation of Norepinephrine in Schizophrenia: Effects of Clonidine in Schizophrenic Patients and Normal Controls.
D. E. Sternberg, D. S. Charney, G. R. Heninger, J. F. Leckman, K. M. Hafstad, and D. H. Landis (1982)
Arch Gen Psychiatry 39, 285-289
   Abstract »    PDF »
Adrenergic Receptor Sensitivity in Depression: Effects of Clonidine in Depressed Patients and Healthy Subjects.
D. S. Charney, G. R. Heninger, D. E. Sternberg, K. M. Hafstad, S. Giddings, and D. H. Landis (1982)
Arch Gen Psychiatry 39, 290-294
   Abstract »    PDF »
Presynaptic Adrenergic Receptor Sensitivity in Depression: The Effect of Long-term Desipramine Treatment.
D. S. Charney, G. R. Heninger, D. E. Sternberg, D. E. Redmond, J. F. Leckman, J. W. Maas, and R. H. Roth (1981)
Arch Gen Psychiatry 38, 1334-1340
   Abstract »    PDF »
Plasma MHPG in Rapid Cyclers and Healthy Twins.
D. C. Jimerson, J. I. Nurnberger Jr, R. M. Post, E. S. Gershon, and I. J. Kopin (1981)
Arch Gen Psychiatry 38, 1287-1290
   Abstract »    PDF »
Conversion of MHPG to Vanillylmandelic Acid: Implications for the Importance of Urinary MHPG.
P. A. Blombery, I. J. Kopin, E. K. Gordon, S. P. Markey, and M. H. Ebert (1980)
Arch Gen Psychiatry 37, 1095-1098
   Abstract »    PDF »
Plasma Free and Conjugated MHPG in Psychiatric Patients: A Pilot Study.
D. R. Sweeney, J. F. Leckman, J. W. Maas, S. Hattox, and G. R. Heninger (1980)
Arch Gen Psychiatry 37, 1100-1103
   Abstract »    PDF »
Urinary 3-Methoxy-4-Hydroxyphenylglycol Circadian Rhythm: Early Timing (Phase-Advance) in Manic-Depressives Compared With Normal Subjects.
T. A. Wehr, G. Muscettola, and F. K. Goodwin (1980)
Arch Gen Psychiatry 37, 257-263
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)